Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04213261 · ClinicalTrials.gov registry record · Phase 3
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
A Phase 3 study of Recessive Dystrophic Epidermolysis Bullosa, sponsored by Castle Creek Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
- 5
- Study locations
NCT04213261 is a Phase 3 study of Recessive Dystrophic Epidermolysis Bullosa that is active but no longer recruiting, run by Castle Creek Biosciences. The registered enrollment target is 6 participants, below the 19-participant average among 5 other Recessive Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (68% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04213261, a Phase 3 study of Recessive Dystrophic Epidermolysis Bullosa, is active but no longer recruiting, sponsored by Castle Creek Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD
Conditions Studied
Interventions
- BIOLOGICAL FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Study Locations (5)
California
- Stanford University - Stanford
Colorado
- Children's Hospital Colorado - Aurora
Florida
- Solutions Through Advanced Research, Inc. - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Texas
- Dell Children's Medical Group - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2037-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04213261
The ClinicalTrials.gov registry entry for NCT04213261 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 19-participant average among 5 other Recessive Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (68% lower). The listed sponsor is Castle Creek Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recessive Dystrophic Epidermolysis Bullosa appearing as the primary indexed condition, and to 1 intervention - of which FCX-007 (dabocemagene autoficel; see below for FCX-007 description) is the first listed.
NCT04213261 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT04213261 about?
NCT04213261 is a clinical study titled "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa". The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD
What is the current status of trial NCT04213261?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2020-06-09. Estimated completion is 2037-07.
What conditions does trial NCT04213261 study?
This clinical trial studies the following conditions: Recessive Dystrophic Epidermolysis Bullosa.
What interventions are being tested in trial NCT04213261?
The interventions under investigation include: FCX-007 (dabocemagene autoficel; see below for FCX-007 description) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04213261?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04213261 being conducted?
This trial has 5 study locations across California, Colorado, Florida, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recessive Dystrophic Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 3
-
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
COMPLETED · Phase 3
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
Long-Term Follow-up Protocol
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.